Annual report [Section 13 and 15(d), not S-K Item 405]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Talphera (Details)

v3.25.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Talphera (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 12, 2024
Apr. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Agreements        
Payments of consideration under RPAs, AAAs and CPPAs     $ 53,000 $ 14,650
Receipts under RPAs, AAAs, and CPPAs     29,248 13,956
Short-term royalty and commercial payment receivables under the cost recovery method     413 14,215
Credit losses on purchased receivables     30,904 1,575
Talphera | Commercial Payment Purchase Agreement        
Agreements        
Threshold amount for royalties and milestones $ 20,000      
Payments of consideration under RPAs, AAAs and CPPAs $ 8,000      
Receipts under RPAs, AAAs, and CPPAs     100  
Allowance for credit losses       $ 0
Credit losses on purchased receivables     7,900  
Write off of allowance for credit losses     $ 7,900  
Talphera | Commercial Payment Purchase Agreement | All customers excluding DoD        
Agreements        
Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive (as a percent) 100.00%      
Royalty percentage entity has the right to fully retain 15.00%      
Talphera | Commercial Payment Purchase Agreement | DoD        
Agreements        
Royalties and milestones entity has the right to receive as a percentage counterparty is entitled to receive (as a percent) 100.00%      
Royalties shared equally with counterparty (as a percent) 75.00%      
Talphera | Alora Pharmaceuticals | Asset Purchase Agreement and Marketing Agreement        
Agreements        
Maximum milestone payments entitled to receive   $ 116,500    
Talphera | Alora Pharmaceuticals | Asset Purchase Agreement and Marketing Agreement | All customers excluding DoD        
Agreements        
Royalties entity has right to receive (as a percent)   15.00%    
Talphera | Alora Pharmaceuticals | Asset Purchase Agreement and Marketing Agreement | DoD        
Agreements        
Royalties entity has right to receive (as a percent)   75.00%